This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obritsch, M. D.
Right arrow Articles by Jung, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obritsch, M. D.
Right arrow Articles by Jung, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4606-4610, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4606-4610.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002

Marilee D. Obritsch, Douglas N. Fish, Robert MacLaren, and Rose Jung*

Antimicrobial Research Laboratory, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado

Received 5 January 2004/ Returned for modification 24 May 2004/ Accepted 28 July 2004

Nosocomial infections caused by Pseudomonas aeruginosa in critically ill patients are often difficult to treat due to resistance to multiple antimicrobials. The purpose of this study was to evaluate antimicrobial resistance among P. aeruginosa isolates from intensive care unit patients in the United States from 1993 to 2002 by using the Intensive Care Unit Surveillance Study database. Over the 10-year period, susceptibility of 13,999 nonduplicate isolates of P. aeruginosa was analyzed. From 1993 to 2002, nationwide increases in antimicrobial resistance were greatest for ciprofloxacin, imipenem, tobramycin, and aztreonam. Rates of multidrug resistance (resistance to ≥3 of the following drugs: ceftazidime, ciprofloxacin, tobramycin, and imipenem) increased from 4% in 1993 to 14% in 2002. The lowest dual resistance rates were observed between aminoglycosides or fluoroquinolones with piperacillin-tazobactam while the highest were for those that included ß-lactams and ciprofloxacin. Ongoing surveillance studies are crucial in monitoring antimicrobial susceptibility patterns and selecting empirical treatment regimens.

* Corresponding author. Mailing address: University of Colorado Health Sciences Center, Department of Clinical Pharmacy, School of Pharmacy, 4200 East Ninth Ave., Campus Box C-238, Denver, CO 80262. Phone: (303) 315-2664. Fax: (303) 315-4630. E-mail: rose.jung{at}uchsc.edu.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4606-4610, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4606-4610.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mulvey, M. R. PhD, Simor, A. E. MD (2009). Antimicrobial resistance in hospitals: How concerned should we be?. CMAJ 180: 408-415 [Full Text]  
  • Wargo, K. A., Wright, B. M., Gupta, R. (2008). The Utility of Fluoroquinolones in the Critically Ill. Journal of Pharmacy Practice 21: 346-355 [Abstract]  
  • Kim, A., Banevicius, M. A., Nicolau, D. P. (2008). In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures. Antimicrob. Agents Chemother. 52: 2497-2502 [Abstract] [Full Text]  
  • Gutierrez, O., Juan, C., Cercenado, E., Navarro, F., Bouza, E., Coll, P., Perez, J. L., Oliver, A. (2007). Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish Hospitals. Antimicrob. Agents Chemother. 51: 4329-4335 [Abstract] [Full Text]  
  • Lodise, T. P., Miller, C. D., Graves, J., Furuno, J. P., McGregor, J. C., Lomaestro, B., Graffunder, E., McNutt, L.-A. (2007). Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance. Antimicrob. Agents Chemother. 51: 417-422 [Abstract] [Full Text]  
  • Eckert, R., Brady, K. M., Greenberg, E. P., Qi, F., Yarbrough, D. K., He, J., McHardy, I., Anderson, M. H., Shi, W. (2006). Enhancement of Antimicrobial Activity against Pseudomonas aeruginosa by Coadministration of G10KHc and Tobramycin. Antimicrob. Agents Chemother. 50: 3833-3838 [Abstract] [Full Text]  
  • Kwon, D. H., Lu, C.-D. (2006). Polyamines Induce Resistance to Cationic Peptide, Aminoglycoside, and Quinolone Antibiotics in Pseudomonas aeruginosa PAO1.. Antimicrob. Agents Chemother. 50: 1615-1622 [Abstract] [Full Text]  
  • Jarvis, T. C., Beaudry, A. A., Bullard, J. M., Ochsner, U., Dallmann, H. G., McHenry, C. S. (2005). Discovery and Characterization of the Cryptic {Psi} Subunit of the Pseudomonad DNA Replicase. J. Biol. Chem. 280: 40465-40473 [Abstract] [Full Text]  
  • Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., Lewis, R. E. (2005). Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 3624-3630 [Abstract] [Full Text]  
  • Fish, D. N., Teitelbaum, I., Abraham, E. (2005). Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 49: 2421-2428 [Abstract] [Full Text]  
  • (2005). Resistant Pseudomonas on the Rise in Intensive Care Units. JWatch Infect. Diseases 2005: 4-4 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»